CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Germline alterations in many genes coding for proteins regulating DNA repair and DNA damage response (DDR) to DNA double-strand breaks (DDSB) have been recognized as pathogenic factors in hereditary cancer predisposition. The ATM-CHEK2-p53 axis has been documented as a backbone for DDR and hypothesized as a barrier against cancer initiation. However, although CHK2 kinase coded by the CHEK2 gene expedites the DDR signal, its function in activation of p53-dependent cell cycle arrest is dispensable. CHEK2 mutations rank among the most frequent germline alterations revealed by germline genetic testing for various hereditary cancer predispositions, but their interpretation is not trivial. From the perspective of interpretation of germline CHEK2 variants, we review the current knowledge related to the structure of the CHEK2 gene, the function of CHK2 kinase, and the clinical significance of CHEK2 germline mutations in patients with hereditary breast, prostate, kidney, thyroid, and colon cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“The competence of the ATM-CHK2-p53 signaling cascade has been hypothesized as a barrier preventing early tumorigenesis [17], inducing cell cycle blockade, apoptosis, or senescence in transformed cells [18].”
BackgroundInherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680
Peng, C.-Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., & Piwnica-Worms, H. (1997) · Science · doi:10.1126/science.277.5331.1501 · Cited by 1,341 · cited 1×
“The interaction with 14-3-3 proteins displaces CDC25C from binding and the dephosphorylation of a CDK1-cyclin B complex, required for its activation before mitotic entry [16,88].”
BackgroundThe Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222 · cited 1×
“The inhibition of CDC25 phosphatases by phosphorylation ensures rapid but transient checkpoint activation, while the activation of p53 is required for longer cell cycle arrest, the induction of senescence, or apoptosis [87].”
BackgroundThe CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis
Falck, J., Mailand, N., Syljuåsen, R. G., Bartek, J., & Lukas, J. (2001) · Nature · doi:10.1038/35071124 · Cited by 1,085
WINPEPI updated: computer programs for epidemiologists, and their teaching potential
Abramson, J. H. (2011) · Epidemiologic Perspectives & Innovations · doi:10.1186/1742-5573-8-1 · Cited by 844 · cited 1×
“* Calculated using WINPEPI [208]; ** CHEK2 = an analysis of the entire coding sequence (dominantly without CNV); otherwise specified if certain CHEK2 variants were genotyped.”
MethodDNA damage signalling guards against activated oncogenes and tumour progression
Bartek, J., Bartkova, J., & Lukas, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210881 · Cited by 521
Cited by
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches
Liu, F., Chen, J., Li, K., Li, H., Zhu, Y., Zhai, Y., Lu, B., Fan, Y., Liu, Z., Chen, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02046-3 · Cited by 326
CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma
Chen, Y., Zhu, Z., Wu, X., Li, H., Guan, W., & Ren, H. (2024) · Cell Death Discovery · doi:10.1038/s41420-023-01777-4 · Cited by 6
Metadata
- Authors
- Stolarova, L., Kleiblova, P., Janatova, M., Soukupova, J., Zemankova, P., Macurek, L., & Kleibl, Z.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-12-12
- Volume
- 9
- Issue
- 12
- Pages
- 2675
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W3110887898
- Cited by
- 190
- References
- 23
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate. https://app.cochat.ai/papers/10.3390/cells9122675
- The paper
- Stolarova, L., Kleiblova, P., Janatova, M., Soukupova, J., Zemankova, P., Macurek, L., & Kleibl, Z. (2020). CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate. Cells. https://doi.org/10.3390/cells9122675
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.